58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 73

58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

Background

Financial toxicity (FT) describes the burden patients face from out-of-pocket costs related to medical care. FT is strongly associated with quality of life and may predict survival. Both direct costs of care and indirect costs such as transportation, child/family care, or lost income may contribute to FT. Patients with low socioeconomic status (SES) and/or members of minority groups (eg, ethnic, racial, religious, linguistic) may be particularly vulnerable to FT. This study aims to measure the change in patient-reported FT (PRFT) during breast cancer treatment among a diverse patient population.

Methods

This is a single-arm, single-institution, longitudinal, noninterventional, prospective cohort survey study of patients undergoing curative-intent breast cancer treatment at Maimonides Cancer Center (MMC), a safety-net hospital in Brooklyn, New York, serving a diverse population, with over 45% of MMC patients having Medicaid or no insurance.

Data collection tools include the Comprehensive Score for Financial Toxicity (COST) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) QLQ-C30 questionnaires. Questionnaires are available in English, Arabic, Cantonese, Mandarin, Russian, and Spanish. Patients complete questionnaires prior to beginning curative-intent breast cancer therapy and repeat them 6 months later, with optional completion at 3, 9, and 12 months after enrollment. At 6 months, we will also ask patients “What do you think would help you feel better about the costs of your treatment?”

The primary objective is to evaluate change in PRFT (measured by COST) during breast cancer therapy. Secondary objectives will evaluate correlations between PRFT and outcomes such as missed appointments, hospitalization rates, and survival. We will also evaluate the predictive value of characteristics such as age, gender, primary language, insurance status, SES, cancer stage, and treatment modalities on PRFT. We hypothesize that PRFT will significantly worsen over the initial 6 months of curative-intent treatment for breast cancer.

Status and Future Work

The study is institutional review board-approved and currently enrolling patients. As of December 15, 2023, 10 patients have been enrolled out of a target of 123. Once complete, this study will measure changes in PRFT among our target population and generate hypotheses on the causes and effects of FT to inform the design of future studies into interventions to ameliorate FT and improve outcomes.

Articles in this issue

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast  Cancer in the United States by Palliative Care Utilization
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
64 Empowering Medical Students to Deliver Breast Health Education:  A Community-Based Initiative
64 Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the  PREDICT Study
66 A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients With Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table